A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, safety and tolerability study in subjects with chronic stable
sensorimotor deficits after ischemic stroke. It has been designed as a double-blind,
placebo-controlled, 2-period crossover study.